CION Ameerpet
Granulosa cell tumours belong to a third family of ovarian tumour, distinct from the epithelial and germ cell types. They produce hormones, which means they usually announce themselves early — and that gives them a considerably better outlook than most ovarian cancer.
Ovarian tumours come in three broad families, depending on which cells they arise from. Epithelial tumours come from the surface cells and account for the large majority of ovarian cancer — these are what CA-125 relates to. Germ cell tumours come from the egg-producing cells and predominate in young women, marked by AFP, beta-hCG and LDH.
The third family is sex cord-stromal, arising from the supporting cells that surround and nurture the developing egg. Granulosa cell tumours are the commonest of these, and they have a defining characteristic that sets them apart from both other families: they produce hormones, usually oestrogen.
That single feature shapes everything about them. Oestrogen produced by the tumour stimulates the uterine lining, causing bleeding — abnormal bleeding in a younger woman, or bleeding after the menopause in an older one. That symptom is obvious, it is taken seriously, and it brings women to a doctor. Which is why granulosa cell tumours are usually found at an early stage, in sharp contrast to the epithelial disease that dominates ovarian cancer statistics.
Epithelial from surface cells, germ cell from egg cells, and sex cord-stromal from the supporting cells.
Usually oestrogen, which stimulates the uterine lining and causes bleeding.
That obvious symptom brings women in, which is why most are found at an early stage.
Granulosa cell tumours are known for late recurrence in a way that is unusual among cancers. Whereas most solid tumours that are going to return do so within the first few years, granulosa cell tumours can recur ten, twenty or even thirty years after apparently successful treatment. This is why follow-up is measured in decades rather than the standard five years, and why being discharged early is the thing to guard against — a woman told at five years that she no longer needs review may be left unmonitored during exactly the period when recurrence remains possible. Source: published series on granulosa cell tumour outcomes; NCCN guidelines.
The presentation differs by age, because the same oestrogen produces different effects at different life stages.
| Life stage | Typical presentation | What usually happens next |
|---|---|---|
| Before puberty (juvenile form) | Precocious puberty — breast development, pubic hair, bleeding in a young child. | Paediatric endocrine and gynaecology assessment; imaging finds the ovarian mass. |
| Reproductive years | Irregular, heavy or unpredictable bleeding; sometimes absent periods. | Pelvic ultrasound assessing ovaries and endometrial thickness. |
| Around the menopause | Erratic bleeding easily mistaken for perimenopause. | The overlap with normal perimenopausal change is why some are found late. |
| After the menopause | Post-menopausal bleeding — the classic presentation of the adult form. | Urgent assessment: transvaginal ultrasound and endometrial sampling. |
| Any age | Abdominal distension, a palpable mass, or acute pain from rupture. | Imaging, tumour markers including inhibin B, and surgical assessment. |
*Because these tumours produce oestrogen, the uterine lining is stimulated — so endometrial hyperplasia and occasionally endometrial cancer can coexist. The endometrium is assessed alongside the ovary. See bleeding after menopause.
Because these tumours make hormones, the hormones themselves become the marker — which is unusually direct.
Inhibin B is a hormone normally produced by granulosa cells in the ovary as part of the feedback loop that regulates the menstrual cycle. In a woman past the menopause, granulosa cell activity has ceased and inhibin B levels are normally very low.
A granulosa cell tumour is made of those same cells, and it continues producing inhibin B. So a raised level in a post-menopausal woman is a meaningful finding, and it is used both to support the diagnosis and to monitor afterwards.
AMH is also produced by granulosa cells and is used similarly. Many people know it as the test for ovarian reserve in fertility assessment, which is the same biology applied to a different question.
Some centres use inhibin B, some use AMH, and some use both. Where either was raised at diagnosis, it becomes the marker for follow-up — which is why it matters to know what yours were at the outset.
CA-125 relates to epithelial tumours, and granulosa cell tumours are not epithelial. It may be normal despite active disease, so relying on it would be misleading — the same problem as using CA-125 in a young woman with a germ cell tumour.
This is a recurring theme across ovarian tumours: the right marker depends on which family of tumour you have. If you have a granulosa cell tumour and are being followed with CA-125 alone, it is worth asking whether inhibin B or AMH should be used instead. See germ cell markers.
Where inhibin B or AMH was raised before treatment and fell afterwards, it becomes a genuinely useful surveillance tool — a rise can signal recurrence, sometimes before symptoms or imaging findings appear.
Given that recurrence can occur decades later, this monitoring continues far longer than for most cancers. As with any marker, a single rise is repeated rather than acted on immediately, and it is read alongside symptoms and imaging.
Because the tumour produces oestrogen, the uterine lining is being continuously stimulated. That can cause endometrial hyperplasia, and in some women a coexisting endometrial cancer.
So assessment of a suspected granulosa cell tumour includes evaluating the endometrium — measuring its thickness on ultrasound and sampling it where indicated. This is a genuinely important step that is occasionally overlooked when attention focuses on the ovarian mass. See endometrial cancer.
Treatment is primarily surgical. Because most are diagnosed at an early stage and usually involve one ovary, fertility-sparing surgery is frequently possible in younger women — removing the affected ovary while preserving the other and the uterus.
Chemotherapy is used in more advanced or recurrent disease rather than routinely for early-stage tumours. At CION chemotherapy is delivered in-house; surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. See fertility and ovarian cancer.
Whether you are being assessed or in long-term follow-up, these warrant contact rather than waiting.
The classic presentation, and it always warrants prompt assessment regardless of anything else.
Given how late these tumours can recur, this is meaningful even decades on.
Where it was raised at diagnosis, a rise during surveillance can signal recurrence before symptoms appear.
Or a palpable mass. Worth assessing rather than attributing to weight or age.
Ask about this. Recurrence decades later is characteristic, so a standard five-year discharge may be too soon.
These tumours can rupture. Same-day assessment rather than a routine appointment.
If you had a granulosa cell tumour years ago and have been discharged, it is reasonable to ask whether ongoing surveillance is appropriate given the late-recurrence pattern.
These tumours can return a decade or more after treatment. Being discharged early is the thing to guard against, not a sign that all is well.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy is delivered in-house at CION; surgery is coordinated with specialist partner centres.
A woman told she has an ovarian tumour will search ovarian cancer survival and find figures drawn overwhelmingly from advanced epithelial disease. Those numbers are not hers, and somebody should say so early rather than leaving her to find out weeks later.
Granulosa cell tumours generally have a considerably better outlook. Most are diagnosed at an early stage, because the oestrogen they produce causes bleeding that gets noticed and acted upon. They tend to grow slowly. And they usually involve one ovary, which makes complete surgical removal — and often fertility preservation — achievable.
The genuine caveat is the one this page keeps returning to: late recurrence. These tumours can return many years after treatment, which is why follow-up is unusually long and why being discharged at five years is worth questioning. That is a reason for sustained surveillance rather than sustained anxiety — the pattern is known, and monitoring for it is straightforward.
Ovarian cancer survival statistics reflect advanced epithelial disease, which this is not.
The hormonal symptoms bring women in, and slow growth means disease is often confined.
Usually one ovary is involved, so fertility-sparing surgery is frequently possible in younger women.
A reason for long surveillance rather than long anxiety. The pattern is known and monitorable.
These tumours are uncommon, which creates a specific problem: general information about ovarian cancer applies poorly to them, and women frequently find themselves reading about a disease that is not theirs. The markers are different, the presentation is different, the outlook is different, and the follow-up schedule is different.
Your first consultation at CION is free and runs to about 45 minutes. Bring your pathology report and any inhibin B or AMH results. The useful conversation is usually about what your actual markers were at diagnosis, what the follow-up plan should be given the late-recurrence pattern, and — if you are a younger woman — whether fertility has been properly addressed.
Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, though it is used in more advanced or recurrent disease rather than routinely for early-stage tumours. Surgery, including fertility-sparing procedures, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case that raises a question is reviewed at a tumour board — which matters particularly for uncommon tumours.
Different markers, different presentation, different outlook, different follow-up. Worth having explained.
What inhibin B or AMH was at diagnosis determines what surveillance can use afterwards.
Given late recurrence, a standard five-year discharge may not be appropriate.
Multidisciplinary review matters most where a tumour type is seen infrequently.
It is a sex cord-stromal tumour — the third family of ovarian tumour, distinct from the epithelial tumours that make up most ovarian cancer and from the germ cell tumours that predominate in young women. It arises from the granulosa cells that normally surround and support the developing egg, and its defining feature is that it produces hormones, usually oestrogen. That oestrogen stimulates the uterine lining and causes bleeding, which is an obvious symptom that brings women to a doctor — which is why most of these tumours are found at an early stage.
Inhibin B is a hormone normally produced by granulosa cells in the ovary as part of the feedback loop regulating the menstrual cycle. After the menopause, granulosa cell activity ceases and levels are normally very low. A granulosa cell tumour is made of those same cells and continues producing inhibin B, so a raised level in a post-menopausal woman is meaningful. It is used to support the diagnosis and, more importantly, for long-term monitoring afterwards. Anti-Mullerian hormone is produced by the same cells and is used similarly.
Because CA-125 relates to epithelial ovarian tumours, and granulosa cell tumours are not epithelial. CA-125 may be entirely normal despite active granulosa cell disease, so relying on it for monitoring would be misleading. This mirrors the same problem as using CA-125 in a young woman with a germ cell tumour. The right marker depends on which family of ovarian tumour you have. If you have a granulosa cell tumour and are being followed with CA-125 alone, it is worth asking whether inhibin B or AMH should be used instead.
Generally considerably better than for the epithelial ovarian cancer that dominates online statistics — and those numbers are not applicable to you. Most granulosa cell tumours are diagnosed at an early stage, because the oestrogen they produce causes bleeding that gets noticed and acted on. They tend to grow slowly, and they usually involve only one ovary, which makes complete surgical removal achievable and often allows fertility preservation in younger women. The genuine caveat is that they can recur many years later, which is why follow-up is unusually long.
Because granulosa cell tumours are known for late recurrence in a way that is unusual among cancers. Most solid tumours that are going to return do so within the first few years, but these can recur ten, twenty or even thirty years after apparently successful treatment. That is why surveillance is measured in decades rather than the standard five years — and why being discharged early is the thing to guard against. If you had one of these tumours years ago and have been discharged from follow-up, it is reasonable to ask whether ongoing surveillance is appropriate.
Because the tumour is producing oestrogen, and that oestrogen continuously stimulates the uterine lining. Unopposed stimulation can cause endometrial hyperplasia — thickening of the lining — and in some women a coexisting endometrial cancer. So assessment of a suspected granulosa cell tumour includes evaluating the endometrium: measuring its thickness on transvaginal ultrasound and taking a sample where it is thickened. This is an important step that is occasionally overlooked when attention focuses on the ovarian mass itself, so it is worth asking whether it has been done.
The first consultation is free and runs to about 45 minutes — bring your pathology report and any inhibin B or AMH results, since what those were at diagnosis determines what surveillance can use afterwards. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, though it is used for more advanced or recurrent disease rather than routinely for early-stage tumours. Surgery, including fertility-sparing procedures, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case is reviewed at a tumour board.